Celiac Disease Pipeline Grows As 25+ Key Pharma Companies Join The Fight For Innovative Treatments Delveinsight
In October 2024, Topas Therapeutics announced positive topline results from its Phase IIa trial of TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept ...
Two Key Metrics That Are Changing the RIA Landscape
In this week's "The Deep Dive," Steven Tenney, a former advisor turned coach, shares key strategies for growing an RIA. He ...
中国日报网5d
Global South's support for multilateralism, open economy key for G20 Summit
The 19th G20 Summit in Rio de Janeiro, Brazil, will count on the strong and consistent support of Global South countries to ...
Democratic jockeying for the 2028 presidential election is already underway
Nearly two dozen Democrats are seen as possible contenders ahead of an invisible primary that will be shaped partly by Trump ...